Table 4.

Future Research Directions in Vascular Cardio-Oncology

More rigorous identification of cardiovascular and cardiometabolic side effects during clinical trials and in the real-world population after drug approval

Cardiovascular adjudications by an independent committee during clinical trials

Multi-institutional registries for identifying vascular and metabolic toxicities once a drug is approved

Open-source data sharing among pharmaceutical companies with cardiovascular toxicities of cancer therapies

Comprehensive and systematic vascular phenotyping via biomarkers and imaging

Personalized/precision medicine in cardio-oncology

Better identification of patients at risk for cardiovascular toxicities during cancer treatment

Single integrated registry with researchers, patients, providers, and clinical diagnostic laboratories entering family history, clinical and research data, and accompanying biospecimens (including DNA) in a deidentified manner

Genetic inquiries for risk of toxicity

Development of better vascular imaging and use in cardio-oncology population

Integration of basic, translational, and clinical research programs in academic cardio-oncology

Cardiovascular clinical and translational models to help elucidate mechanisms of toxicity

Development of more robust model cell systems (eg, induced pluripotent stem cells) and animal models for preclinical testing of novel compounds

Research on mechanisms of common risk factors (including genetic risk factors) that are shared between cancer and cardiovascular disease

Education of clinicians and patients about cardiovascular toxicities of cancer therapies

Web-based platforms for access to known vascular toxic effects of novel anticancer drugs